Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04387318
Other study ID # 08527219.0.0000.5346
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date March 10, 2023

Study information

Verified date May 2023
Source Universidade Federal de Santa Maria
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is a significant current public health problem, characterized by the presence of limited airflow. However, COPD has important manifestations beyond the lungs, the so-called systemic effects. These included dysfunction of peripheral and respiratory muscles. The growing amount of evidence has shown that patients with COPD also present important deficits in postural balance and consequently, increased risk of falling. As an essential part of the management of COPD, pulmonary rehabilitation (PR) alleviates dyspnea and fatigue, improves exercise tolerance and health-related quality of life, and reduces hospital admissions and mortality for COPD patients. Exercise is the key component of PR, which is composed of exercise assessment and training therapy. Currently, two modalities of therapy have been suggested as complementary to pulmonary rehabilitation: inspiratory muscular training (IMT) and neuromuscular electrical stimulation (NMES). Based on the premise that peripheral and respiratory muscle dysfunction can negatively impact postural control of patients with COPD, and given the importance of balance as a modifiable risk factor for falls, it is important to investigate whether the use of these therapeutic modalities (IMT and/or NMES) is capable of improving the short-term effects of pulmonary rehabilitation and also promoting improved balance.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 10, 2023
Est. primary completion date March 10, 2023
Accepts healthy volunteers No
Gender All
Age group 55 Years to 80 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of COPD, in stages II, III and IV, according to criteria of the Global Initiative for COPD (GOLD); - Clinically stable, i.e., absence of infections or exacerbations in the last 3 months; - Medical team allows patient to exercise - Availability of attending the rehabilitation program. Exclusion Criteria: - Unstable primary pathologies (cardiovascular, renal, metabolic, psychiatric); - Hemodynamic instability; - Nutritional supplementation on the 4 weeks preceding the study; - Severe hearing or visual impairment recorded on patient chart or self-referred; - Obesity (BMI > 30 kg/m2); - Neurological or musculoskeletal condition that severely limits mobility and postural control, thus making it impossible to carry out the assessments; - Electronic devices, such as heart pacemakers and implantable cardioverter defibrillator; - Skin injuries and infection where electrodes would be placed; - Prior participation in pulmonary rehabilitation programs 3 months previous to the study; - Vertigo; - Active smoker and/or alcoholic; - Neurological impairment or cerebellar lesions; - Deficit in cognitive function; - Severe vitamin D deficiency; - Physically active.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Multimodal training
IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks. NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks. Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
IMT + Pulmonary Rehabilitation
IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8. Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
NMES + Pulmonary Rehabilitation
NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks. Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
Pulmonary Rehabilitation
Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.

Locations

Country Name City State
Brazil Universidade Federal de Santa Maria Santa Maria Rio Grande Do Sul

Sponsors (1)

Lead Sponsor Collaborator
Universidade Federal de Santa Maria

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Static postural balance Static postural balance will be assessed on a portable force platform (AccuSway Plus, AMTI®, MA, USA) using the center of pressure displacement amplitude in the anteroposterior direction (COP) (cm). Post-intervention (change after 8 weeks of training)
Primary Static postural balance Static postural balance will be assessed on a portable force platform (AccuSway Plus, AMTI®, MA, USA) using the area of ellipse (AE) (cm2). Post-intervention (change after 8 weeks of training)
Primary Static postural balance Static postural balance will be assessed on a portable force platform (AccuSway Plus, AMTI®, MA, USA) using the velocity of displacement of center of pressure (COPvel) (cm/s). Post-intervention (change after 8 weeks of training)
Primary Static postural balance Static postural balance will be assessed on a portable force platform (AccuSway Plus, AMTI®, MA, USA) using the center of area of pressure and area of ellipse (AE) (cm2). Post-intervention (change after 8 weeks of training)
Secondary Static postural balance Static postural balance (%) will assessed through Foam-Laser dynamic posturography. Post-intervention (change after 8 weeks of training)
Secondary Static and dynamic postural balance Static and dynamic postural balance will assessed using the Berg Balance Scale (score points). Scores range from 0 to 56, with higher scores indicating better balance. Post-intervention (change after 8 weeks of training)
Secondary Static and dynamic postural balance Static and dynamic postural balance will assessed using the Balance Evaluation Systems Test (score points). The total score of the test (108 points) will be calculated with a percentage score (0-100%) and higher scores indicate better balance performance. Post-intervention (change after 8 weeks of training)
Secondary Dynamic postural balance Dynamic postural balance will assessed using the Timed Up and Go (seconds). A faster time indicate a better functional performance and a score of =12 seconds used as a cut-point. Post-intervention (change after 8 weeks of training)
Secondary Balance confidence questionnaire Balance confidence questionnaire will measured through the Activities Specific Balance Confidence Scale (total score points). The questionnaire contains 16 items scored on a range from 0% to 100% (0 indicating no confidence and 100 indicating full confidence). Post-intervention (change after 8 weeks of training)
Secondary Balance confidence questionnaire Balance confidence questionnaire will measured through Falls Efficacy Scale-International (total score points). The total score ranges from 16 to 64 points. Higher values indicate less fall-related self-efficacy (and more concern about falling). Post-intervention (change after 8 weeks of training)
Secondary Peripheral muscle strength Handgrip strength and quadriceps muscle strength will be assessed by dynamometry, respectively, Kgf and Newtons. Post-intervention (change after 8 weeks of training)
Secondary Respiratory muscle strength and inspiratory muscle endurance Respiratory muscle strength (cmH2O) and inspiratory muscle endurance (cmH2O) will measured through digital pressure manometry and incremental and constant test, respectively Post-intervention (change after 8 weeks of training)
Secondary Quadriceps femoris and diaphragm thickness Quadriceps femoris and diaphragm thickness will measured by ultrasonography Post-intervention (change after 8 weeks of training)
Secondary Submaximal level of functional capacity Submaximal level of functional capacity will measured by 6-minute walk test Post-intervention (change after 8 weeks of training)
Secondary Health-related quality of life at 8 week Health-related quality of life will measured by Saint George's Respiratory Questionnaire. Overall scores range from 0 (no effect on quality of life) to a maximum score of 100 (maximum perceived distress). Post-intervention (change after 8 weeks of training)
Secondary Oxidant profile The oxidant profile will be assessed by Dichlorofluorescein Diacetate - DCF-DA (picomoles / mL). Post-intervention (change after 8 weeks of training)
Secondary Oxidant profile The oxidant profile will be assessed by Thiobarbituric Acid Reactive Substances -TBARS (nmol de MDA/mL). Post-intervention (change after 8 weeks of training)
Secondary Oxidant profile The oxidant profile will be assessed by Advanced Oxidation Protein Products - AOPPs (µmol/L). Post-intervention (change after 8 weeks of training)
Secondary Oxidant profile The oxidant profile will be assessed by Total Oxidant Status - TOS (mmol Trolox Equiv/L). Post-intervention (change after 8 weeks of training)
Secondary Antioxidant profile The antioxidant profile will be assessed by Ferric Reducing Antioxidant Power - FRAP- (µmol/L) Post-intervention (change after 8 weeks of training)
Secondary Antioxidant profile The antioxidant profile will be assessed by Total Antioxidant Capacity- CAT (mmol Trolox Equiv/L). Post-intervention (change after 8 weeks of training)
Secondary Muscle damage Muscle damage will assessed through creatine phosphokinase (total CPK) (U/L). Post-intervention (change after 8 weeks of training)
Secondary Muscle damage Muscle damage will assessed through lactate dehydrogenase (LDH) (U/L). Post-intervention (change after 8 weeks of training)
Secondary Muscle damage Muscle damage will assessed through lactate parameter (mg/dL). Post-intervention (change after 8 weeks of training)
Secondary DNA damage DNA damage will assessed by means of the Comet and micronucleus assay Post-intervention (change after 8 weeks of training)
Secondary Endothelial function Endothelial function will assessed through nitrite/nitrate oxide (NOx) (µmol/L) Post-intervention (change after 8 weeks of training)
Secondary Peripheral muscle resistance of the lower limbs Peripheral muscle resistance of the lower limbs will assessed through 30-second Sit-to-Stand tests (repetitions) Post-intervention (change after 8 weeks of training)
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy